Transcription
MOVING NA PODIATRIC MEDICAL ASSOCIATIONISSUE FOUR WINTER 2018IN THIS ISSUEPRESIDENT’S MESSAGEWENDY WINCKELBACH, DPM IPMA PRESIDENTHIPPA COMPLIANCEIN TEXT MESSAGINGPAGE 3BAKO DIAGNOSTICSA NAIL DYSTROPHYDIAGNOSTICS LEADERPAGE 4IPMA 2018 ANNUALCONVENTION WRAP-UPPAGE 6JOINT NATIONALPODIATRIC CAC-PIACREPRESENTATIVES’MEETINGPAGE 8IPMA EXECUTIVEDIRECTOR ELECTED TOAPMAPAC BOARDPAGE 8APMA VICTORYPAGE 9 OMEONE ANSWERTHE PHONE!PAGE 10PAC REPORTSPAGE 11As my term of office nears its end there are many I would like to thank fortheir service to the association. I have the utmost respect for our current andpast Board members and Trustees. We have been very fortunate to have suchgreat leadership. Their vibrant input into the decision-making process isvital to an association responsive to the needs of its membership. With thatsaid, in order to continue this level of experience we need to cultivate newleadership. If you are interested in joining a committee or getting involved,please do not hesitate to contact me or the IPMA office. We need new leadersto keep IPMA healthy, especially young physicians. We must make sure IPMA is meeting the needs ofthe next generation of podiatrist.Our association remains in a strong financial state. We anticipate finishing 2018 with a seventh straightyear of net positive in the IPMA budget. This is allowing the IPMA to continue to grow its strategicrainy day fund.It was great seeing everyone at the Annual Convention this past October. I enjoyed reconnecting withfriends and colleagues while getting great educational content. Thank you to Dr. Patrick DeHeer forputting together such a great program. I attended both the IPMA Annual Convention and the MidwestPodiatry Conference in Chicago.Thank you to all who attended the convention. I believe that a strong convention is key to the successof the IPMA and hope that all who attend bring someone new in 2019 and encourage those who didnot attend to do so next year.If you have any questions or concerns, please contact the association so we can continue to serve ourmembership in the best way possible.
LIMITED PODIATRICRADIOGRAPHYONLINEEDUCATIONALPROGRAMThe Indiana State Department of Health (ISDH) requires allpodiatric medical assistants who take x-rays to be licensedas a Limited Podiatric Radiographer. The IPMA wants toremind the membership of its Limited Podiatric Radiographyprogram that meets the ISDH requirements and is designedto instruct the podiatry assistant in the safe and effective useof x-rays in the podiatric practice.At the successful conclusion of the program, the applicantwill have the proficiency and skill necessary to obtain theLimited Podiatric Radiography license and will receive aCertificate of Completion. The Certificate, the completedApplication for Proficiency Certification for LimitedRadiographer and signed x-ray log should be sent to theIPMA. Questions? Contact the IPMA office at 888.330.5589.Click here to learn more and register today.
ENSURING HIPPA COMPLIANCE IN TEXT MESSAGINGThe use of mobile phones and other wireless technology inpatient care — termed “mHealth” — is a significant trend in thehealthcare industry. Older technologies, such as pagers, are slowcompared to devices today; thus, many healthcare providers andstaff members find that text messaging provides quick access tothe information they need to make healthcare decisions.Yet, healthcare providers and staff need to be cognizant ofprivacy and security concerns when using text messaging.Typical short message service (SMS) texting does not offer thesecurity necessary for sending protected health information(PHI). As a result, patient privacy might be compromised ifunauthorized individuals can view texted data.Additionally, multiple carriers might be involved in relayingand routing text messages, messages can remain on servers inunencrypted formats, and no guarantee exists that the intendedperson will receive and read the message.1 If unsecure textingresults in HIPAA violations, costly penalties could ensue.Podiatry practices that permit the use of mobile devices fortexting health information (whether the devices are organizationowned or personally owned) should implement policies toensure that PHI sent via mobile networks complies with HIPAAregulations.An initial consideration for podiatry practices is determininghow text messaging activities should be incorporated into healthrecord documentation policies. HIPAA specifies that individualshave the right to view and amend PHI used to make clinicaldecisions about their care, which might include informationsent via text messages. As such, podiatry practices that allowtext messaging should develop policies “requiring annotation ofthe medical record with any ePHI that is received via text and isused to make a decision about a patient.”2Security of PHI is a top concern for all types of healthcareorganizations and providers. Although HIPAA does notspecifically prohibit communicating PHI through text messaging,a system of administrative, physical, and technical safeguardsmust be in place to ensure the integrity of the PHI “in transit.”31.2.3.4.5.6.7.Therefore, to ensure HIPAA compliance in texting, podiatrypractices must use secure messaging systems.Accrediting organizations also might provide guidance orstandards related to texting. For example, The Joint Commissionrequires that healthcare employees send text messages througha secured messaging platform that includes a secure sign-onprocess, encrypted messaging, delivery and read receipts, dateand time stamps, customized message retention timeframes, anda specified contact list for individuals authorized to receive andrecord orders.4When evaluating potential messaging systems, look fortechnology that offers multi-level encryption (e.g., encryption ofstored data, transmitted data, and data within the application).The technology also should be capable of operating on variousdevices, such as mobile phones running various operatingsystems, tablets, and desktop computers.5 Other features of asecure text messaging system to consider include:yyData storage on a secure private server with backupyyA remote option for removing/disabling the applicationfrom a mobile device in the event that the device is lost orstolenyyAutomatic logout after a period of inactivityyyThe ability to function on various wireless frequencies andWi-FiyyThe ability to track and confirm message deliveryyyThe ability to set a maximum message data life (e.g., 30days)6Podiatry practices also should consider the potential benefits ofcomprehensive messaging systems, rather than single-purposesystems. Comprehensive messaging system should easilyintegrate with the organization’s calendar, directory, customerrelationship management system, single sign-on capabilities, anddocument-sharing service.7A final consideration is selecting a messaging system that offersinstant access to documents, images, and resources withinconversations, so podiatrists and staff members don’t have toswitch apps (or context) to access important information.Is text messaging HIPAA compliant? HIPAA Journal. Retrieved from iant/Greene, A. H. (2012, April). HIPAA compliance for clinician texting. Journal of AHIMA, 83(4), 34-36.Is text messaging HIPAA compliant? HIPAA Journal.McGee, M. K. (2016). Joint Commission delays lifting secure text messaging ban. InfoRiskToday. Retrieved from ng-secure-text-messaging-ban-a-9275Jansen, J. (2014). mHealth will drive physician demand for secure text messaging in 2014. Retrieved from 2014Ibid.7 Advantages of HIPAA compliant texting apps. Zinc. Retrieved from http://content.zinc.it/Ebook eBook-7-advantages-of-HIPAA-complaint-texting.pdf3
BAKO DIAGNOSTICS A NAIL DYSTROPHYDIAGNOSTICS LEADERBako Diagnostics is the leading diagnostic laboratory forpodiatric medicine and one of the podiatric profession’s principalsources of educational sponsorship. For over ten years, it hasdeveloped an innovative research and diagnostic medical modeldedicated to the advancement of the field of podiatry.“Each specimen that arrives at our laboratory represents apodiatric patient,” said Ted Hull, BakoDx CEO. “Because ofthat, we work diligently to exceed all expectations and deliverexceptionally detailed reports, services and therapeutic treatmentrecommendations to improve patient care and outcomes.”BakoDx services to the podiatric clinician range fromhistopathologic examination of bone, soft tissue, and skin/nail,to microbiology, molecular DNA testing, histopathology andepidermal nerve fiber density (ENFD) analysis. With a uniquefocus on pathology of the lower extremity, BakoDx continues tobe the nation’s leading provider of nail unit dystrophy diagnostictesting and services. Since it was formed, BakoDx has analyzedmore than 1.6 million nail dystrophy cases, using conventionaland molecular techniques.ANALYSIS WITH DNA TECHNOLOGYThe BakoDx onychodystrophy DNA test is a real-timepolymerase chain reaction (PCR) technology that producesresults within 24-48 hours, the shortest turnaround time in theindustry. Compare that with several weeks of waiting for fungalnail culture results.Clinical diagnosis by examination alone can often be inaccurate.The BakoDx onychodystrophy DNA test establishes the causativeIT’S REALLY EXPENSIVE TOTREAT THE WRONG ORGANISMTarget Treatment withBako’s Onychodystrophy DNA VITY24-48 REQUIREDFor details, call: 855-422-5628Learn more: onychodystrophy.comScan to download clinical white paper1. Bako Diagnostics' internal data; 2. Based on FDA product labeling indications and usage4bakodx.com
agent of nail infection with 99.9 percent analytical specificity. Thisallows physicians to deliver fast, evidence-based results to targetand treat infectious pathogens implicated in onychomycosis,including dermatophytes, saprophytes and/or yeast.Recently, BakoDx’s proprietary onychodystrophy DNA test wasenhanced to detect the most common bacterial cause of nailinfection, Pseudomonas aeruginosa, the causative agent of greennail syndrome.“The addition of P. aeruginosa to the onychodystrophy panelenables clinicians to more fully define the causes of infectiousonychodystrophy and allow for appropriate therapy,” said WayneL. Bakotic, D.O., and BakoDx Co-Founder.BETTER TOGETHER: DNA HISTOLOGYBakoDx’s onychodystrophy DNA test is designed to complementhistopathology. Because only 50 percent of suspectedcases of onychomycosis are caused by infection, BakoDx’sonychodystrophy DNA test and histology adds the benefit oftesting the sample for trauma, neoplastic processes and noninfectious nail diseases.A comprehensive evaluation of nail unit dystrophy and potentialtherapeutic regimen recommendations for the underlyingetiology is then shared with the physician. This detaileddiagnoses report provides podiatric medical professionals withthe highest sensitivity and specificity available, with the goal ofbetter patient care and outcomes.By detecting and identifying the correct causative agent ofdisease, unnecessary expense to patients and payers areeliminated. Most national health insurance payers requiregenus/species identification for preauthorization of anti-fungalprescriptions. BakoDx’s in-network services are available to morethan 250 million covered lives, including all five national healthplans, and fully compliant patient-friendly billing policies. Inaddition, the BakoDx onychodystrophy DNA test is covered byMedicare and most healthcare insurance plans.REPORTING MALIGNANCIESThe Dermatopathologists and Pathologists at BakoDx havedetected thousands of malignancies annually from specimenssubmitted to its laboratory from physicians throughout the U.S.Through the use of a simple biopsy techniques, patients maybenefit from the best outcome prognosis with the least morbidity.“Bako Diagnostics is in a unique position as thedermatopathology market leader for podiatrists to collect,analyze, study and share their findings with the profession,”said Dr. William P. Scherer, Senior Podiatric Medical Advisorfor BakoDx. “The incidence of lower extremity skin cancerrepresents an often overlooked and understudied disease.”SUPPORTING PODIATRIC MEDICINEIn addition to an expert team of dermatopathologists andpathologists available to diagnose and consult with physicianclients, BakoDx has a Podiatric Advisory Board comprisedof leaders in the podiatric medical profession. This boardwas assembled to advise the company as it further advancesits mission and commitment to offering the highest qualitylaboratory service. BakoDx’s Clinical Consultant Team augmentsthe Advisor Board to further promote educational outreachinitiatives.Through its Fellowship Program, a two-week podiatricdermatology rotation, BakoDx contributes to the on-siteeducation of podiatric residents. The fully-funded rotationserves as a foundation for the physician’s practice of podiatricdiagnostics throughout their careers.“It has truly been an honor and privilege to partner with theIndiana Podiatric Medical Association and we look forward toour continued affiliation,” said Shawna Shapero, VP of BakoDxCorporate and Professional Relations.Pathologists at Bako Diagnostics are available for consultation from 7a.m. to 7 p.m. ET. Visit BakoDx.com or call 855-422-5628 to order or formore information.PRACTICE FOR SALEIPMA wanted to make members aware of a long standing, diversified podiatric practice for sale. Thepractice is mainly in Northwest Indiana, but also a small part in Illinois. Doctor to retire and move.Ground floor rental. Allowed to sublease so may increase patient load or keep as part time. Emailreplies to: doctorfootstep@gmail.com.5
IPMA 2018 ANNUAL CONVENTION WRAP-UPOver 200 doctors, speakers andexhibitors came together at the IPMA93rd Annual Fall Convention andMembership Meeting at the HyattRegency in downtown IndianapolisHighlights of this year’s conventionincluded:yyEducational seminars and leadingpodiatric presenters that providedover 23 CME hours for doctorattendees.yyTradeshow with 40 exhibitors thatincluded a new format allowing formore opportunities toyyAnnual Meeting presentations andreports on current IPMA activityand vision for the future. IPMAmembers can receive electroniccopies of the 93rd Annual Reportby emailing the IPMA office atinpma@indianapodiatric.org orcalling 888-330-5589.yyLegislative update and reportby IPMA Governmental AffairsConsultant Glenna Shelby.ELECTION OF IPMA BOARD OFTRUSTEES AND OFFICERSyyPresident - Richard Loesch, DPMyyPresident-Elect - Brian Damitz,DPMyyFirst Vice President - SandraRaynor, DPMyySecond Vice President –Christopher Grandfield, DPMyySecretary-Treasurer - Cathy Coker,DPMyyImmediate Past President – WendyWinckelbach, DPMyyNorth Trustee – Kathleen NeuhoffToepp, DPMyyCentral Trustee – Nathan Graves,DPMyySouth Trustee – Zahid Lahda, DPM2018 IPMA AWARDS BANQUETOn Saturday, October 20th, the IPMAheld its annual awards banquet to honorthose members who have supportedthe IPMA and the podiatric profession.IPMA Awards Luncheon was moderatedby Jeffrie C. Leibovitz. This year’s awardrecipients included:yyPatricia Moore, DPMDr. T. H. Clarke AchievementAwardThis award is IPMA’s highest award,and is bestowed upon the memberwho has demonstrated not onlycontributions to his professionbut also service in behalf of thepodiatric welfare of the public andservice to the community at large.yyKenneth Krueger, DPMIPMA Meritorious Service AwardPresented only to IPMA membersfor long-time service rendered tothe profession of podiatric medicineperformed within the stateAssociation or for an outstandingcurrent record in a specific
93rd Annual Fall ConventionOctober 18-21, 2018Hyatt Regency Indianapoliscategory or categories which meritsrecognition, but does not meetthe IPMA Podiatrist of the Yearstandards.yyTina ZorluGinny Jewel Podiatric Staff of theYear AwardPresented to a staff member whohas demonstrated contributions tothe Association or has demonstratedoutstanding leadership andcommitment to his or her podiatricoffice. This award nomination is tobe submitted by a DPM who wishesto honor his or her staff member fortheir outstanding work.The IPMA also recognized the followingdoctors achieving these milestones:yy25 Years of MembershipJames Meede, DPMMark Runkle, DPMyyRetirementDr. Pratap GohilFinally, a moment of silence was observedfor the past presidents who passed awayin 2018 including Dr. Jack Glick, DPM(IPMA President 1975) and Dr. HarnoldAron, DPM (IPMA President 1970).SAVE THE DATE FOR THE IPMA 2019ANNUAL CONVENTIONMark your calendar now for next year’sAnnual Convention, October 10-13,2019. Next year’s convention will againbe held at the Hyatt Regency IndianapolisDowntown. We appreciate the doctors,vendors and speakers that attended thisyear, and look forward to returning todowntown Indianapolis next year.
18TH ANNUAL JOINT NATIONAL PODIATRICCAC-PIAC REPRESENTATIVES' MEETINGyyensuring that you have strong and non-biased clinicalresearch evidence to support a requested change in policy;andyyconsidering the environmental constraints for the MedicalDirector in terms of his or her direct ability to immediatelyresolve a purported issue – i.e. go through the appropriatechannels.WENDY WINCKELBACH, DPM,CAC REPRESENTATIVEI recently attended the 18th Annual Joint National PodiatricCarrier Advisory Committee (CAC)-Private Insurance AdvisoryCommittee (PIAC) Representatives meeting, held in Baltimore,MD, November 2, 2018, on behalf of the IPMA. This annualmeeting presents a unique opportunity for CAC and PIACrepresentatives to hear from experts and leaders in both privateand public insurance issues. It also allows for representatives tohear from other CAC and PIAC representatives about new andongoing trends, both regional and national that might impactour members.This year’s meeting featured a slate of industry speakerscovering the full spectrum of reimbursement, and providedstrong guidance for how your local representatives are integralfor success. The main focus this year was fostering effectivecommunications between CAC and PIAC representatives and theprivate and public medical directors to resolve reimbursementand coverage issues, as well as communications between CACand PIAC representatives and podiatric colleagues to helpeducate them on the latest insurance issues. Speakers includedAetna Medical Director Chris Jagmin, MD, and WPS HealthInsurance Medical Director Robert Kettler, MD. Common themesof both Dr. Jagmin and Dr. Kettler included:yydeveloping and maintaining a relationship with yourMedical Director before an issue arises;To this end, extended group discussions were held to allowrepresentatives to bring up ongoing or new public and privatepayer issues in their states and receive input and advice fromtheir peers who may have dealt with similar issues in the past.Numerous states expressed issues with billing with the 25and 59 modifier, as well as routine foot care claim denials.Additionally a common complaint was increasing frustrationwith Medicare Advantage plans not providing reimbursementfor services otherwise covered under Original Medicare.Representatives were able to give advice and guidance on how toeffectively resolve these issues where they had experience in theirown states.Attendees also heard from Cindy Moon, MPP, MPH, vicepresident at Hart Health Strategies, for a Medicare policy updateincluding more information on APMA’s recent E/M codingvictory that thwarted CMS’ efforts to a implement a separate,lower value E/M code for podiatrists. APMA is hosting a webinarfor members on December 6 at 8:00 p.m. EST to go over thesechanges but important finalizations for the 2019 MedicareIPMA E
Bako Diagnostics is the leading diagnostic laboratory for . focus on pathology of the lower extremity, BakoDx continues to be the nation’s leading provider of nail unit dystrophy diagnostic . plans, and fully compliant patient-friendly billing polici
